إعلان
إعلان

NVCR

NVCR logo

NovoCure Limited Ordinary Shares

14.30
USD
برعاية
+0.53
+3.87%
٠٦ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

14.20

-0.10
-0.72%

تقارير أرباح NVCR

النسبة الإيجابية المفاجئة

NVCR تفوق 23 من 40 آخر التقديرات.

57%

التقرير التالي

بيانات التقرير القادم
٢٣ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$172.30M
/
-$0.40
التغير الضمني من Q3 25 (Revenue/ EPS)
+3.05%
/
+21.21%
التغير الضمني من Q4 24 (Revenue/ EPS)
+6.84%
/
-34.43%

NovoCure Limited Ordinary Shares earnings per share and revenue

On ٣٠ أكتوبر ٢٠٢٥, NVCR reported earnings of -0.33 USD per share (EPS) for Q3 25, beating the estimate of -0.42 USD, resulting in a 23.15% surprise. Revenue reached 167.20 مليون, compared to an expected 162.37 مليون, with a 2.98% difference. The market reacted with a -4.90% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 المحللين forecast an EPS of -0.40 USD, with revenue projected to reach 172.30 مليون USD, implying an زيادة of 21.21% EPS, and زيادة of 3.05% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
٢٣ ديسمبر ٢٠٢٥ إلى ربع سنوي4 25
تقدير
-$0.12
الفعلي
-$0.06
مفاجئة
+50.98%
الأسئلة الشائعة
For Q3 2025, NovoCure Limited Ordinary Shares reported EPS of -$0.33, beating estimates by 23.15%, and revenue of $167.20M, 2.98% above expectations.
The stock price moved down -4.9%, changed from $13.48 before the earnings release to $12.82 the day after.
The next earning report is scheduled for ٢٣ فبراير ٢٠٢٦.
Based on 10 المحللين, NovoCure Limited Ordinary Shares is expected to report EPS of -$0.40 and revenue of $172.30M for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان